Takumi Sugimoto

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

Junji Hiraga, Akihiro Tomita, Takumi Sugimoto et al. · Blood · 2009 · 253 citations · Full text

Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy

Akihiro Tomita, Junji Hiraga, Hitoshi Kiyoi et al. · International Journal of Hematology · 2007 · 54 citations

Hematological Malignancy, Lymphoid Neoplasia, Rituximab-containing Chemotherapy +10

Dual-stimuli responsive liposomes using pH- and temperature-sensitive polymers for controlled transdermal delivery

Naoko Yamazaki, Takumi Sugimoto, Mitsuhiro Fukushima et al. · Polymer Chemistry · 2017 · 52 citations

Nanomedicine, Transdermal Delivery, Engineering +15

Escape mechanisms from antibody therapy to lymphoma cells: Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation

Takumi Sugimoto, Akihiro Tomita, Junji Hiraga et al. · Biochemical and Biophysical Research Communications · 2009 · 49 citations · Full text

Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer

Yuri Ogura, Nobutaka Kataoka, Yusuke Kunimatsu et al. · Thoracic Cancer · 2020 · 31 citations · Full text